SiRNA/rss/search.php?qu=siRNA/rss/search/rss/search.php?qu=siRNA/rss/search.php?qu=siRNA/rss/search.php?qu=siRNA/rss/search.php?qu=siRNA RSS

Filtered By:
Specialty: Cancer & Oncology
Drug: Xeloda

This page shows you your search results in order of date.

Order by Relevance | Date

Total 468 results found since Jan 2013.

Chemo-immune cell therapy by intratumoral injection of adoptive NK cells with capecitabine in gastric cancer xenograft model
CONCLUSION: Although NK cell therapy could effectively decrease the mitotic count in vivo, the obtained findings indicated lesser potency than MC despite ex vivo activation. In order to enhance NK cell therapy effectiveness, suppressive features of the tumor microenvironment and inhibitory immune checkpoints blockade should be considered.PMID:37736341 | PMC:PMC10509737 | DOI:10.34172/bi.2022.26386
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Zeinab Ghazvinian Shahrokh Abdolahi Mohammad Ahmadvand Amir Hossein Emami Samad Muhammadnejad Hamid Asadzadeh Aghdaei Jafar Ai Mohammad Reza Zali Iman Seyhoun Javad Verdi Kaveh Baghaei Source Type: research

A real-world retrospective study to evaluate the reliability of cetuximab plus capecitabine versus capecitabine as maintenance therapy in patients with RAS and BRAF wild-type metastatic colorectal cancer
CONCLUSION: A maintenance therapy using cetuximab plus capecitabine improved survival in patients with metastatic CRC and is well tolerated by patients.PMID:37725905 | DOI:10.1159/000533528
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Jun Li Hang Zhang Xuli Guo Shaoting Dong Yi Li Weizhen Huang Xia Yuan Source Type: research

Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial)
BMJ Open. 2023 Sep 12;13(9):e069499. doi: 10.1136/bmjopen-2022-069499.ABSTRACTINTRODUCTION: Recent preclinical studies have discovered unique synergism between radiotherapy and immune checkpoint inhibitors, which has already brought significant survival benefit in lung cancer. In locally advanced rectal cancer (LARC), neoadjuvant radiotherapy plus immune checkpoint inhibitors have also achieved surprisingly high pathological complete response (pCR) rates even in proficient mismatch-repair patients. As existing researches are all phase 2, single-cohort trials, we aim to conduct a randomised, controlled trial to further clar...
Source: Cancer Control - September 12, 2023 Category: Cancer & Oncology Authors: Kai Pang Yun Yang Dan Tian Na Zeng Shun Cao Shen Ling Jiale Gao Pengfei Zhao Hao Wang Yuanyuan Kong Jie Zhang Guangyong Chen Wei Deng Zhigang Bai Lan Jin Guoju Wu Danyang Zhu Yue Wang Jiaolin Zhou Bin Wu Guole Lin Yi Xiao Zhidong Gao Yingjiang Ye Xin Wang Source Type: research

Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P-Values
Oncologist. 2023 Sep 8:oyad203. doi: 10.1093/oncolo/oyad203. Online ahead of print.NO ABSTRACTPMID:37682036 | DOI:10.1093/oncolo/oyad203
Source: The Oncologist - September 8, 2023 Category: Cancer & Oncology Authors: Antonio Tito Fojo Alfred I Neugut Source Type: research

Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer
Oncologist. 2023 Sep 8:oyad202. doi: 10.1093/oncolo/oyad202. Online ahead of print.NO ABSTRACTPMID:37682029 | DOI:10.1093/oncolo/oyad202
Source: The Oncologist - September 8, 2023 Category: Cancer & Oncology Authors: David J Benjamin Vinay Prasad Source Type: research

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
CONCLUSIONS AND RELEVANCE: The substantial superior outcomes in patients receiving first-line CAPTEM treatment highlight its potential as an effective treatment strategy for patients with metastatic NET.PMID:37676712 | DOI:10.1093/oncolo/oyad257
Source: The Oncologist - September 7, 2023 Category: Cancer & Oncology Authors: Çağlar Ünal Abdulmunir Azizy Senem Karabulut Didem Ta ştekin Arif Aky ıldız Serkan Ya şar Şuayib Yalçın Ey üp Çoban T ürkkan Evrensel Ziya Kalkan Zeynep Oru ç S ümeyra Derin Zeynep Hande Turna Do ğan Bayram Fahriye Tu ğba Köş Mehmet Ali Source Type: research

Mytomicin-C, Metronomic Capecitabine, and Bevacizumab in Patients With Unresectable or Relapsed Pseudomyxoma Peritonei of Appendiceal Origin
CONCLUSION: Metronomic capecitabine, bevacizumab, and MMC are an active regimen in advanced and progressive PMP and favorably compares with historical series.PMID:37657955 | DOI:10.1016/j.clcc.2023.08.005
Source: Clinical Colorectal Cancer - September 1, 2023 Category: Cancer & Oncology Authors: Filippo Ghelardi Alessandra Raimondi Federica Morano Giovanni Randon Alessandra Pannone Marcello Guaglio Giacomo Mazzoli Vincenzo Nasca Massimo Milione Giuseppe Leoncini Giovanna Sabella Gabriella Francesca Greco Bianca Rosa Lampis Margherita Galassi Sara Source Type: research

A polymorphism in ABCA2 is associated with neutropenia induced by capecitabine in Japanese patients with colorectal cancer
CONCLUSIONS: We found that ABCA2 polymorphism was significantly associated with systemic exposure to capecitabine and capecitabine-induced neutropenia in Japanese patients with CRC.PMID:37653272 | DOI:10.1007/s00280-023-04584-x
Source: Clinical Colorectal Cancer - August 31, 2023 Category: Cancer & Oncology Authors: Yukitaka Shibata Natsumi Matsumoto Remi Murase Yutaro Kubota Hiroo Ishida Ken Shimada Ken-Ichi Fujita Source Type: research

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20